Kornimate/medical-research-clean huggingface dataset:
bupropion and weight control for smoking cessation - 1

Conditions: Tobacco Use Disorder

Summary: the purpose of this study is to determine whether the addition of bupropion (zyban) to cognitive behavioral therapy (cbt) will enhance longer-term tobacco abstinence in women.

although rates of smoking have declined, the decrease in prevalence has been much less pronounced in women than in men, and women are particularly vulnerable to ongoing smoking-related morbidity and mortality. one important reason for gender differences in smoking cessation is concern about cessation-related weight gain among women, which is associated with poorer cessation outcome. we previously documented that cognitive behavior therapy to minimize weight concerns (cbt) was effective in promoting cessation and controlling weight gain among weight concerned women smokers. the current study is a randomized, double-blind, controlled trial to determine whether the addition of bupropion (zyban) to cbt (12 sessions over 14 weeks, with 6 booster sessions) will enhance longer-term abstinence. bupropion was the clear medication of choice for this trial because it is efficacious in promoting smoking cessation, attenuates cessation-related weight gain (particularly in women), and relieves negative mood, which appears more common in weight-concerned women. four hundred fifty weight concerned women smokers will be randomized to either cbt for weight concerns plus standard cessation or standard smoking cessation only and six months of either bupropion (zyban) or placebo (2 x 2 design). primary outcome will be rates of smoking abstinence at 1 year and time to relapse across the four treatment conditions. in addition, we will determine the effects of these treatments on tobacco withdrawal, mood, and weight. results of this investigation will provide information on the relative efficacy of the cbt intervention and bupropion alone and in combination and the utility of drug and counseling strategies that are specifically tailored for a high-risk population.

Eligibility criteria:
inclusion criteria: * smoke at least 10 cigarettes per day * report concern about cessation-related weight gain * motivated to quit smoking exclusion criteria: * currently pregnant, lactating, or no medically approved method of contraception * major medical problem * history of seizure disorder or head injury * current or historical psychosis or bipolar disorder * history of alcohol or substance abuse within previous year * current or historical eating disorder * use of antidepressant medication, monoamine oxidase inhibitor or lithium with previous month * multiple drug allergies * current major depressive disorder

Keywords: smoking cessation women bupropion weight concerns weight
ultrasound biomicroscopy - apoptosis

Conditions: Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Basal Cell

Summary: a group of researchers at the ontario cancer institute/princess margaret hospital have discovered that a very specific form of cell death 'apoptosis' can be detected using high-frequency ultrasound imaging. this type of cell death is recognized to occur in tumours in response to various different chemotherapeutic drugs and in response to radiation therapy. this group of researchers has confirmed that high-frequency ultrasound can detect apoptosis in response to tumour treatments experimentally using cell culture and experimental animal systems. the ultrasound approach is now being evaluated clinically in a 3-year clinical trial enrolling a target of 200 patients including hodgkin's disease and non-hodgkin's disease lymphoma patients, melanoma patients and patients with basal cell carcinoma. our hope is to be able to use this type of imaging system in the future to clinically monitor the effects of therapy on tumours and rapidly detect tumours which are not responding so that changes in therapy can be made much quicker than presently possible.


Eligibility criteria:
inclusion criteria: * lymphoma patients with superficial lesions prior to starting chemotherapy or after relapse of disease * patients with superficial melanoma lesions * patients with superficial basal cell carcinoma lesions * informed consent exclusion criteria: -
drug use investigation for toviaz

Conditions: Overactive Bladder (OAB)

Summary: the purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.


Eligibility criteria:
inclusion criteria: * patients prescribed fesoterodine (toviaz). exclusion criteria: * there are no exclustion criteria

Keywords: toviaz fesoterodine post marketing surveillance japanese overactive bladder oab good post marketing practice regulatory post marketing commitment plan
chronic evaluation of respicardia therapy

Conditions: Sleep Disordered Breathing; Cheyne Stokes Respiration; Periodic Breathing; Sleep Apnea; Central Sleep Apnea

Summary: the purpose of this study is to determine the chronic safety and efficacy of phrenic nerve stimulation on central sleep apnea (csa). clinically, csa events translate into sleep fragmentation, excessive daytime sleepiness, reduced exercise capacity, and possibly ventricular arrhythmias. the study is chronic in nature, such that subjects will undergo the implantation of an implantable pulse generator and stimulation lead. a sensing lead may also be placed during the initial implant procedure. subjects will be followed for up to six-months on therapy to assess respiratory and heart failure outcomes. following the six-month therapy visit, subjects will enter into a long-term follow-up phase until the completion of the study. it is anticipated that data obtained in this study will show that the proposed intervention can modify respiration with a low incidence of adverse effects. the results of this trial are intended to be used to develop a subsequent protocol for pivotal study.


Eligibility criteria:
inclusion criteria: * candidate is at least 18 years old * candidates with known recent history of periodic breathing, as evidenced by an overnight polysomnogram (psg) within 60 days of the implant procedure demonstrating: * apnea-hypopnea index (ahi) greater than or equal to 20 events/hr * predominantly central origin (central apnea events comprise 50% or more of all apnea events) * limited obstructive events (obstructive apneas comprise less than 20% of the ahi) exclusion criteria: * candidates who are pregnant * candidates with baseline oxygen saturation less than or equal to 90% on a stable fio2 * candidates with severe copd * candidates with a history of cerebrovascular accident (cva), myocardial infarction, coronary artery bypass grafting (cabg) surgery, or percutaneous coronary intervention (pci) within the 3 months prior to the study * candidates with unstable angina * candidates with history of primary pulmonary hypertension

Keywords: sleep disordered breathing cheyne stokes respiration periodic breathing sleep apnea central sleep apnea
sildenafil efficacy study on time walk from peripheral arterial desease patients (stade ii) with arterial claudication

Conditions: Peripheral Arterial Occlusive Disease

Summary: efffect of a single dose oral intake of sildenafil or placebo on the walking capacity on treadmill of pad patients with claudication

sildenafil 100mg or placebo oral intake 2 hours before the treadmill test safety and security control throughout the period of drug efficacy (approx 4 hours) evaluation of maximal walking distance for a constant load treadmill test (3.2 kml/h 10% slope)

Eligibility criteria:
inclusion criteria: * patient with peripheral arterial desease stade ii * patient with vascular claudication for at least 3 months * patient able to perform a treadmill walking test with time to walk \< 5min exclusion criteria: * patient suffering from ischemia * previous angina or myocardial * patient treated with nitrates drugs * patient with severe renal insufficiency * patient with severe hepatic insufficiency * patient with hypotension
vestibular treatment in adolescents following sport related concussion

Conditions: Vestibular Disorder

Summary: each year, nearly 2 million children and adolescents have a sport-related concussion (src) in the u.s., but 57% of them do not receive appropriate clinical care following their injury. these injuries involve a wide range of symptoms including headache, dizziness, and sleep problems; and cognitive, emotional, visual, and vestibular impairment. the investigators have developed a clinical treatment model for src that addresses the heterogeneity of this injury using different clinical subtypes or profiles that inform precision interventions. to date, the investigators have identified cognitive, anxiety/mood, post-traumatic migraine, cervical, oculomotor, and vestibular clinical profiles. patients with vestibular clinical profiles- involving dizziness, environmental sensitivity, and imbalance- are common (60-65% of concussions), and have worse outcomes and longer recovery following src. consequently, the investigators have developed and applied precision vestibular treatments that can be matched to specific impairments and symptoms to actively treat patients with vestibular clinic profiles.

to determine using a rct design the effectiveness of standard of care behavioral management (i.e., sleep, walking, nutrition, stress management) to standard of care behavioral management (i.e., sleep, walking, nutrition, stress management) (standard of care) plus vestibular exercises (i.e., balance, eye-head movements, and dynamic walking exercises) (vestibular) for reducing recovery time, symptoms, and vestibular (balance, eye-head movements) and cognitive (e.g., memory, processing speed) impairment in adolescent patients with vestibular clinical profiles following sport--related concussion (src).

Eligibility criteria:
inclusion criteria: * must be 12-18 years of age. * must be diagnosed with a sport-related concussion within the last 3-10 days. * must be identified by upmc sports medicine clinicians as having clinical presentation of a vestibular profile of concussion. * must report an increase of +2 of symptom provocation on voms (from baseline symptom report) on either vor or vms measurements during voms assessment. exclusion criteria: * more than 3 concussions including presenting injury; * current history or pre-existing vestibular disorder; * current orthopaedic injury; * history of brain surgery or tbi (based on glasgow coma scale of \<13); * history of substance abuse; * history of neurological disorder (seizure disorder, epilepsy, brain tumors or malformations); * current concussion is non-sport related. the above exclusion factors are known to influence recovery and thus if any one exclusion criterion is met, the athlete will be unable to participate in the current study.

Keywords: adolescent concussion
temozolomide in patients with newly diagnosed anaplastic oligodendroglioma and mixed oligoastrocytoma

Conditions: Oligoastrocytoma, Mixed; Anaplastic Oligodendroglioma

Summary: rationale: standard therapy for anaplastic oligodendrogliomas and mixed oligoastrocytomas includes radiation and chemotherapy. however, due to the potential long-term central nervous system toxicity from radiation, researchers speculate that it may be better to reserve radiation therapy for progressive disease. in addition, some patients with anaplastic oligodendroglioma and mixed oligoastrocytoma have unusually chemosensitive tumors. previous research indicates that brain tumor patients with a deletion of the 1p chromosome have a higher response to the chemotherapy drug temozolomide.

temozolomide has demonstrated clinical antitumor efficacy against malignant gliomas at both relapse and initial diagnosis. this drug appears to have less adverse effects compared to other drugs used against brain tumors. therefore, temozolomide is often better tolerated in brain tumor patients compared to other brain tumor drugs. the current study builds on previous research to test the efficacy of chemotherapy alone in patients with anaplastic oligodendroglioma and mixed oligoastrocytoma. purpose: this study will evaluate response rate, or how the disease size changes in patients, and survival without disease growth, in patients with anaplastic oligodendroglioma and mixed oligoastrocytoma treated with temozolomide. quality of life will also be assessed in this patient population treated with the study regimen. treatment: study participants will be treated with the drug temozolomide. this drug will be administered in oral pills. temozolomide will be taken for seven consecutive days followed by seven days without the drug. this treatment schedule of seven days on temozolomide followed by seven days off will continue throughout the study. several tests and exams will be given to closely monitor patients. mri scans will be performed every 8 weeks to measure disease response. temozolomide as a study drug will be given to study participants for a total of 8 week four cycles. however, treatments will be discontinued due to disease growth or unacceptable adverse events.

Eligibility criteria:
inclusion criteria: * anaplastic oligodendroglioma or mixed oligoastrocytoma * age \> 18 * karnofsky status \> 70% * adequate bone marrow, liver and renal function exclusion criteria: * prior chemotherapy or cranial irradiation

Keywords: newly diagnosed
efficacy of chlorhexidine as a final irrigant in single-visit root canal treatment

Conditions: Root Canal Infection

Summary: ninety asymptomatic maxillary anterior teeth with periapical lesions were treated in single versus multiple visit root canal treatment. half of the teeth were randomly assigned to the single-visit (sv) group and received an additional final rinse with 2% chx before obturation. the other teeth were treated in multiple visits (mv) with calcium hydroxide dressing. all patients were recalled and investigated clinically and radiographically for 24 months.

the aim of the study was to evaluate postoperative pain and radiographic evidence of periapical healing in teeth with apical periodontitis treated in a single visit with an additional final irrigation using 2% chlorhexidine and to compare the results with conventional multiple-visit root canal treatment (rct) with an intracanal calcium hydroxide dressing as a control group. ninety asymptomatic maxillary anterior teeth with periapical lesions were treated by a single operator using the step-back technique with manual instrumentation with 2.5% sodium hypochlorite (naocl) and 5% ethylenediaminetetraacetic acid (edta) as irrigants. half of the teeth were randomly assigned to the single-visit (sv) group and received an additional final rinse with 2% chlorhexidine (chx) before obturation. the other teeth were treated in multiple visits (mv), after completion of root canal instrumentation calcium hydroxide paste was placed into the root canal and root canal obturation was performed in second visit. all patients were recalled and investigated clinically and radiographically for 24 months. postoperative pain at 24-48 hours and changes in apical bone density indicating radiographic healing were evaluated statistically using the mann-whitney u-test followed by the friedman and the wilcoxon tests (α=.05).

Eligibility criteria:
inclusion criteria: * patients with a non-contributory medical history, * mature maxillary anterior teeth with periapical lesions (\< 5 mm), * diagnosed as asymptomatic apical periodontitis. exclusion criteria: * clinical symptoms, drainage, * more than 5 mm loss of periodontal attachment, * previous endodontic treatment, * non-restorable tooth.

Keywords: single visit root canal treatment, chlorhexidine
study to assess the impact on calcium levels when hemodialysis patients with secondary hyperparathyroidism (shpt) switch from cinacalcet to etelcalcetide

Conditions: Hyperparathyroidism, Secondary

Summary: this is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (amg 416).


Eligibility criteria:
inclusion criteria * subject is 18 years of age or older at the time of informed consent. * subject must be receiving maintenance hemodialysis 3 times weekly for at least 8 weeks. * subject must have shpt as defined by having a mean of 3 consecutive central laboratory screening predialysis serum parathyroid hormone (pth) values ≥ 200 pg/ml, with measurements obtained from 3 different calendar weeks in the 4-week screening period while receiving cinacalcet. * subject must have a mean of 3 consecutive central laboratory screening predialysis serum corrected calcium (cca) values ≥ 7.5 mg/dl, with measurements obtained from 3 different calendar weeks in the 4-week screening period while receiving cinacalcet. * subject must be on a stable dose of cinacalcet before screening (defined as no dose change within the 4 weeks prior to screening). * other inclusion criteria may apply. exclusion criteria * currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s). * subject has received amg 416 in a prior clinical trial of amg 416 (also known as kai-4169). * subject has known sensitivity to any of the products or components of amg 416 to be administered during dosing. * subject is unwilling to use effective contraception during the study, and for women, up to a period of up to 3 months after the last dose of amg 416. * subject is pregnant or nursing. * anticipated or scheduled parathyroidectomy during the study period. * subject has received a parathyroidectomy within 6 months prior to dosing. * other exclusion criteria may apply.

Keywords: secondary hyperparathyroidism (shpt), chronic kidney disease (ckd), hemodialysis, parathyroid hormone (pth), hypocalcemia, bone and mineral metabolism
pharmacist led educational intervention on qol, medication adherence & satisfaction on patients with type 1 dm

Conditions: Diabetes Mellitus, Type 1

Summary: there was no previous study in iraq to evaluate the efficacy of pharmacist-led educational intervention on patient glycemic control, quality of life and medication adherence among type 1 diabetic patients in iraq. improving diabetes patients' information's about their disease control, the role of insulin and the right technique to administer it, how to deal with hyper- and hypoglycemia, about their diet and exercise. it is important to conduct a study to evaluate the pharmacist's role in education and improving patients' quality of life.

aim of the study: the aim of the current study is to evaluate the impact of pharmacist-led educational intervention on glycemic control, quality of life and medication adherence among type 1 diabetic patients.

Eligibility criteria:
inclusion criteria: * - patients age ≥ 16 years old who can speak and read the arabic language. * had been diagnosed with t1dm for at least 6 months ago. * had uncontrolled hyperglycemia (glycosylated hemoglobin hba1c ≥7% and/or fasting blood glucose \>130 mg/dl) * patients on the same regimen the last 3 months. * patients (or parents) acceptance to participate in the study. exclusion criteria: * 1-patient who have hearing, speech or cognitive deficits that would impair understanding of the questions and receiving the education. 2- patients with comorbid conditions that may interfere with the study such as asthma, thyroid disorders, adrenal gland disorders, celiac disease, or significant renal impairment. 3-patients who are taking corticosteroids. 4- patients who required changing their insulin regimen, increasing the dose \>20% of the previous dose. (21) 5- patients with conditions that affect red blood cell turnover (hemolytic and other anemias, g-6-pd deficiency, recent blood transfusion, use of drugs that stimulate erythropoiesis, end stage kidney disease and pregnancy. 6-patients unwilling to participate.
decision making in neonatology : a qualitative study

Conditions: Premature Birth

Summary: this study aimed to describe and understand the decision making process in neonatology in situations of limiting of withdraw life sustaining treatments, by conducting interviews with physicians from one neonatology unit.


Eligibility criteria:
inclusion criteria: * physicians in charge of new born babies for whom a decision making regarding limiting or withdrawing treatments is emerging. * physicians' informed consent to participate to an interview * parents' informed consent to collect data concerning their new born. exclusion criteria: - not fluent french speaker
assessment of oral health knowledge, attitude and behaviour of dental students in cairo university

Conditions: Oral Health Knowledge, Attitude and Behaviour of Dental Students

Summary: the knowledge, behaviour and attitude of oral health professionals reflects their awareness and understanding of oral preventive measures, which will have significant impact on their delivery of public oral health promotion in the future. they are expected to set an example for positive oral health behaviour among other college students, family members and their patients. various external factors like sociodemographic factors like age, gender, marital state, occupation, and number of family members play a major role in oral hygiene. the relationships between various modifiable factors needs to be assesses in a vast manner. there were some researches about oral health knowledge, behaviour and attitude in correlation to socio-demographic data, of dental students in other countries, but little was known in egypt. dental students are expected to play a critical role in instructing public oral health for improving their patient's, families, and friends. in addition, it may pave the way to develop new programs to encourage needful oral health practices.


Eligibility criteria:
inclusion criteria: * preclinical and clinical dental students, faculty of dentistry, cairo university through the academic year 2024-2025. exclusion criteria: * dental students from other universities. * internship dental students. * post-graduate dental students.
a smart, "always -on" health monitoring system

Conditions: Premature Birth

Summary: this is a pilot study is to test a wireless, skin-sensor device against current technology in the nicu to monitor vitals

this is a single center, prospective, observational study that will recruit subjects from lurie children's hospital and prentice women's hospital to test a new wireless vitals monitor against the current vitals monitors used in the nicu. patients will be neonates in different age brackets.

Eligibility criteria:
inclusion criteria: * neonates in different age cohorts from ages 25 weeks gestational age to fullterm infants or infants up to 6 months of age, selected with assistance of nicu staff * currently in nicu and requiring monitoring for heart rate, ecg, respiratory rate, temperature, and pulse oximetry * parents able to understand and provide informed consent for study * infants enrolled in the pre-vent study (sub-study only) exclusion criteria: * over 6 months of age * hemodynamic or other instability precluding testing of new monitoring with concurrent standards * infants at imminent risk of death and neonates with a skin abnormality that precludes assessment

Keywords: premature wireless vitals vitals monitor